These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Inactivation of INH and effectiveness of chemotherapy in pulmonary tuberculosis]. Gipp ZI Vrach Delo; 1974 Jan; (1):104-5. PubMed ID: 4468550 [No Abstract] [Full Text] [Related]
6. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid. Ylitalo P; Auterinen L; Marttinen A; Koivula T Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440 [TBL] [Abstract][Full Text] [Related]
7. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis]. Ellard GA Cas Lek Cesk; 1984 Feb; 123(6):158-64. PubMed ID: 6697364 [No Abstract] [Full Text] [Related]
8. [Rate of acetylation of isoniazid in pulmonary tuberculosis and its relationship with effect and side-effects of treatment (author's transl)]. Zhang LX Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1981 Dec; 4(6):349-51. PubMed ID: 7344873 [No Abstract] [Full Text] [Related]
9. Importance of acetylation and oxidation in inactivation of isonicotinic acid hydrazide preparations. Smirnov GA Fed Proc Transl Suppl; 1966; 25(1):72-6. PubMed ID: 5322111 [No Abstract] [Full Text] [Related]
10. [Indicators of INH inactivation determined using a biological method and its use in monitoring antitubercular treatment]. Czaplińska-Jóźwiak E; Szymański A; Dutkiewicz J Pneumonol Pol; 1986 Dec; 54(12):535-40. PubMed ID: 3588330 [No Abstract] [Full Text] [Related]
11. [Determination of the phenotype of INH inactivation in pulmonary tuberculosis by means of an indirect method on the model of sulfamethazine]. Powłowska I; Rakowska Z Pneumonol Pol; 1978 Aug; 46(8):605-12. PubMed ID: 714703 [No Abstract] [Full Text] [Related]
12. [Isoniazid pharmacokinetics in the combined chemotherapy of tuberculosis]. Sokolova GB; Vilenskaia RN; Ivleva AIa; Galenko NN; Ziia AV Probl Tuberk; 1981 Oct; (10):24-8. PubMed ID: 7312844 [No Abstract] [Full Text] [Related]
13. [Significance of the isoniazid inactivation in the therapy of pulmonary tuberculosis]. Gol'dshteĭn VD; Ioffe RA; Ponomareva ES Probl Tuberk; 1970; 48(1):34-9. PubMed ID: 5425443 [No Abstract] [Full Text] [Related]
14. Isoniazid-induced acne and pellagra. Occurrence in slow inactivators of isoniazid. Cohen LK; George W; Smith R Arch Dermatol; 1974 Mar; 109(3):377-81. PubMed ID: 4273616 [No Abstract] [Full Text] [Related]
15. [Clinical significance of the inactivation of tubazid in the endobronchial method of treatment of destructive pulmonary tuberculosis]. Kanevskaia SS; Rzhavskov IuV Probl Tuberk; 1967; 45(10):44-8. PubMed ID: 5617546 [No Abstract] [Full Text] [Related]
16. Incidence of isoniazid acetylation phenotypes in North Indians. Gupta RC; Nair CR; Jindal SK; Malik SK Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):259-64. PubMed ID: 6746149 [TBL] [Abstract][Full Text] [Related]
17. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Ellard GA Tubercle; 1984 Sep; 65(3):211-27. PubMed ID: 6385429 [No Abstract] [Full Text] [Related]
18. [Pharmacokinetics of isoniazid in patients with pulmonary tuberculosis]. Protsiuk RG; Petrenko VI Sov Med; 1985; (3):94-8. PubMed ID: 4023845 [No Abstract] [Full Text] [Related]
19. [Isoniazid metabolism and the indicators of bioelectric activity of the brain in patients with tuberculosis during treatment with increased doses of isoniazid]. Vilenskaia RN; Chelnokova NV Probl Tuberk; 1976; 3():46-9. PubMed ID: 967856 [No Abstract] [Full Text] [Related]
20. [Incidence of hepatic changes in relation to the isoniazid acetylator phenotype]. Pilheu JA; De Salvo MC; Manchinu I; de Negroni NR; Szemzo J Medicina (B Aires); 1980; 40(4):382-6. PubMed ID: 7207170 [No Abstract] [Full Text] [Related] [Next] [New Search]